These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26246357)

  • 1. Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients.
    Calcagno A; Atzori C; Romito A; Vai D; Audagnotto S; Stella ML; Montrucchio C; Imperiale D; Di Perri G; Bonora S
    J Neurovirol; 2016 Feb; 22(1):88-92. PubMed ID: 26246357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis.
    Calcagno A; Romito A; Atzori C; Ghisetti V; Cardellino C; Audagnotto S; Scarvaglieri E; Lipani F; Imperiale D; Di Perri G; Bonora S
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):187-193. PubMed ID: 27826896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid biomarkers in patients with central nervous system infections: a retrospective study.
    Di Stefano A; Alcantarini C; Atzori C; Lipani F; Imperiale D; Burdino E; Audagnotto S; Mighetto L; Milia MG; Di Perri G; Calcagno A
    CNS Spectr; 2020 Jun; 25(3):402-408. PubMed ID: 31130152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy.
    Du Pasquier RA; Jilek S; Kalubi M; Yerly S; Fux CA; Gutmann C; Cusini A; Günthard HF; Cavassini M; Vernazza PL;
    AIDS; 2013 Jan; 27(2):203-10. PubMed ID: 23032410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau).
    Krut JJ; Price RW; Zetterberg H; Fuchs D; Hagberg L; Yilmaz A; Cinque P; Nilsson S; Gisslén M
    Virulence; 2017 Jul; 8(5):599-604. PubMed ID: 27435879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small cisterno-lumbar gradient of phosphorylated Tau protein in geriatric patients with suspected normal pressure hydrocephalus.
    Djukic M; Spreer A; Lange P; Bunkowski S; Wiltfang J; Nau R
    Fluids Barriers CNS; 2016 Aug; 13(1):15. PubMed ID: 27581842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals--correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels.
    Andersson LM; Hagberg L; Fuchs D; Svennerholm B; Gisslén M
    J Neurovirol; 2001 Dec; 7(6):542-7. PubMed ID: 11704886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.
    Peterson J; Gisslen M; Zetterberg H; Fuchs D; Shacklett BL; Hagberg L; Yiannoutsos CT; Spudich SS; Price RW
    PLoS One; 2014; 9(12):e116081. PubMed ID: 25541953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low cerebrospinal fluid Amyloid-βeta 1-42 in patients with tuberculous meningitis.
    Stroffolini G; Guastamacchia G; Audagnotto S; Atzori C; Trunfio M; Nigra M; Di Stefano A; Di Perri G; Calcagno A
    BMC Neurol; 2021 Nov; 21(1):449. PubMed ID: 34784880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta amyloid levels in cerebrospinal fluid of HIV-infected people vary by exposure to antiretroviral therapy.
    Fields JA; Swinton MK; Soontornniyomkij B; Carson A; Achim CL
    AIDS; 2020 Jun; 34(7):1001-1007. PubMed ID: 32073451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seropositivity and reactivations of HSV-1, but not of HSV-2 nor VZV, associate with altered blood-brain barrier, beta amyloid, and tau proteins in people living with HIV.
    Trunfio M; Di Girolamo L; Ponzetta L; Russo M; Burdino E; Imperiale D; Atzori C; Di Perri G; Calcagno A
    J Neurovirol; 2023 Feb; 29(1):100-105. PubMed ID: 36352195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.
    Balasa M; Vidal-Piñeiro D; Lladó A; Antonell A; Bosch B; Castellanos F; Bargalló N; Bartres-Faz D; Molinuevo JL; Sánchez-Valle R
    J Alzheimers Dis; 2012; 30(3):605-16. PubMed ID: 22426017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
    Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
    JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
    Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
    Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and predictors of blood-brain barrier damage in the HAART era.
    Calcagno A; Alberione MC; Romito A; Imperiale D; Ghisetti V; Audagnotto S; Lipani F; Raviolo S; Di Perri G; Bonora S
    J Neurovirol; 2014 Oct; 20(5):521-5. PubMed ID: 24973194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.